logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

EBacc fails to make substantial impact on GCSE selections

12 October 2012

Despite the introduction of the English Baccalaureate (EBacc), pupils are continuing to select GCSE subjects they enjoy, perform well at and are likely to assist with career choices, according to new research commissioned by the Department for Education (DfE).

The EBacc is not a qualification in itself, but represents the achievement of grade A2 - C at GCSE in the core academic subjects.

The research highlighted that although 98% of schools offer the GCSE subjects required for the EBacc, the proportion of pupils choosing a combination which could lead to it has only marginally changed since 2011 (49% 2012 compared with 46% 2011).

The proportion of schools which have amended their curriculum or option blocks in response to the EBacc has dropped this year compared with 2011, and is expected to decrease further in 2013. As such it is possible that the impact of the EBacc on subject choices has peaked at insignificant.

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up